The Patented Medicine Prices Review Board in Canada has launched the first phase of consultations on the development of new guidelines relating to its contentious drug pricing mechanism.
Stakeholders To ‘Voice Concerns’ On Future Guidelines For Canada’s Controversial Pricing Mechanism
In-person and virtual roundtables next month will let pharma companies have their say on the development of new guidelines relating to the Patented Medicine Prices Review Board’s contentious new pricing method.
More from Canada
• By
An initiative run by health technology appraisal (HTA) bodies in the US, Canada and England is looking at how non-traditional treatment benefits, such as the value of hope and scientific spillover, can inform appraisals and understanding of a product’s value.
• By
The Canadian regulator says its current policy on identifying and labeling drug products in “kits” is insufficient to address the diverse types of co-packaged drug products that are entering the market.
• By
Canada’s new guidance on rare disease registries is based on international guidelines, but in some areas there remains work to ensure that implementation of some recommendations is feasible in the Canadian context.
• By
As part of efforts to modernize its clinical trials framework, the Canadian regulator is looking to better facilitate expanded access clinical trials, which allow investigational drugs to reach patients with serious conditions before they are approved.
More from North America
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
One CDRH employee said the cuts already are having a major effect on morale.
• By
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.